Skip to main content
Journal cover image

Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?

Publication ,  Journal Article
Becker, A; Eichelberg, C; Sun, M
Published in: Cancer
June 1, 2015

Duke Scholars

Published In

Cancer

DOI

EISSN

1097-0142

Publication Date

June 1, 2015

Volume

121

Issue

11

Start / End Page

1906 / 1907

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Male
  • Kidney Neoplasms
  • Interferon-alpha
  • Humans
  • Female
  • Carcinoma, Renal Cell
  • Antineoplastic Combined Chemotherapy Protocols
  • 4206 Public health
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Becker, A., Eichelberg, C., & Sun, M. (2015). Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer, 121(11), 1906–1907. https://doi.org/10.1002/cncr.29255
Becker, Andreas, Christian Eichelberg, and Maxine Sun. “Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?Cancer 121, no. 11 (June 1, 2015): 1906–7. https://doi.org/10.1002/cncr.29255.
Becker, Andreas, et al. “Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?Cancer, vol. 121, no. 11, June 2015, pp. 1906–07. Pubmed, doi:10.1002/cncr.29255.
Journal cover image

Published In

Cancer

DOI

EISSN

1097-0142

Publication Date

June 1, 2015

Volume

121

Issue

11

Start / End Page

1906 / 1907

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Male
  • Kidney Neoplasms
  • Interferon-alpha
  • Humans
  • Female
  • Carcinoma, Renal Cell
  • Antineoplastic Combined Chemotherapy Protocols
  • 4206 Public health
  • 3211 Oncology and carcinogenesis